Earnings Releases·Nov 12, 2026, 4:03 PM ET

CV Sciences, Inc. — Third Quarter 2026 Earnings Summary

Revenue decreased 7.0% year-over-year to $3.0 million, while gross margin improved to 50.0% and operating expenses fell 11.6% YoY to $1.6 million.
The company returned to profitability with a net loss of $93,000 (vs. $382,000 loss YoY), driven by a $0.5 million legal settlement gain and reduced expenses, resulting in positive adjusted EBITDA of $32,000.
Management maintains a focus on cost discipline and product innovation, noting that new products launched since 2023 comprised 48% of Q3 revenue, though total units sold declined 4.7% due to regulatory headwinds.
The company continues to monitor restrictive federal hemp regulations scheduled for December 11, 2026, while strengthening its cash position to $0.3 million and working capital to $0.7 million.